From a therapeutic perspective, this spatial dependency introduces a significant challenge: SLAMF7-targeting antibodies, intended to eliminate SLAMF7-expressing tumor cells, may inadvertently bind SLAMF7 on effector CD8+ T cells, marking them for Fc-mediated clearance. Here, CD8A is linked to neoplasm.